Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer.
Drug repositioning refers to the identification of new therapeutic indications for drugs already approved. Albendazole and ricobendazole have been used as anti-parasitic drugs for many years; their therapeutic action is based on the inhibition of microtubule formation. Therefore, the study of their properties as antitumor compounds and the design of an appropriate formulation for cancer therapy is an interesting issue to investigate. The selected compounds are poorly soluble in water, and consequently, they have low and erratic bioavailability. In order to improve their biopharmaceutics properties, several formulations employing cyclodextrin inclusion complexes were developed. To carefully evaluate the in vitro and in vivo antitumor activity of these drugs and their complexes, several studies were performed on a breast cancer cell line (4T1) and BALB/c mice. In vitro studies showed that albendazole presented improved antitumor activity compared with ricobendazole. Furthermore, albendazole:citrate-β-cyclodextrin complex decreased significantly 4T1 cell growth both in in vitro and in vivo experiments. Thus, new formulations for anti-parasitic drugs could help to reposition them for new therapeutic indications, offering safer and more effective treatments by using a well-known drug.
['Priotti|Josefina|J|', 'Baglioni|María Virginia|MV|', 'García|Agustina|A|', 'Rico|María José|MJ|', 'Leonardi|Darío|D|', 'Lamas|María Celina|MC|', 'Menacho Márquez|Mauricio|M|']
D015766:Albendazole D000818:Animals D000977:Antiparasitic Agents D001682:Biological Availability D049109:Cell Proliferation D003505:Cyclodextrins D058492:Drug Repositioning D005260:Female D006801:Humans D061986:MCF-7 Cells D051379:Mice D008807:Mice, Inbred BALB C D011897:Random Allocation D016896:Treatment Outcome D064726:Triple Negative Breast Neoplasms D014961:X-Ray Diffraction D047392:beta-Cyclodextrins
repositioning cyclodextrin albendazole breast cancer cell line